Form 4: Janux Therapeutics Director Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Eric Dobmeier was granted 5,500 restricted stock units and 15,500 stock options by Janux Therapeutics.
Summary
- Director Eric Dobmeier acquired 5,500 restricted stock units (RSUs) on June 11, 2026.
- The director was also granted 15,500 stock options with an exercise price of $13.66 per share.
- The RSUs vest on the earlier of June 11, 2027, or the date of the next annual stockholder meeting.
- The stock options vest in equal monthly installments over 12 months, fully vesting by the next annual meeting.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Equity grants align the interests of the director with those of the shareholders.
- The transaction reflects continued commitment from the board member to the company's long-term performance.
Negatives
- The issuance of equity results in minor dilution to existing shareholders.
Risks
- Vesting is contingent upon the director's continuous service to the company.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director compensation.
Industry Context
StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the biotechnology sector to ensure long-term alignment with corporate milestones and shareholder value.
Comparison to Industry Standards
- The grant structure is consistent with standard director compensation packages for mid-cap biotechnology firms.
- Vesting schedules tied to annual meetings are common practice to ensure board stability.
Stakeholder Impact
- Shareholders experience minor dilution from the issuance of new equity.
Next Steps
- Director to continue service to satisfy vesting requirements.
- Monitoring of future annual stockholder meetings for vesting triggers.
Key Dates
| Date | Description |
|---|---|
| 06/11/2026 | Date of the equity grant transaction. |
| 06/12/2026 | Date the Form 4 was signed and filed. |
| 06/11/2027 | Vesting date for the restricted stock units. |
| 06/10/2036 | Expiration date for the stock options. |
Keywords
Janux Therapeutics, JANX, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.